UPC APP 67755/2024

—·EP4026488: TRANSCUTANEOUS ANALYTE SENSOR SYSTEMS AND METHODS

Verfahrensdetails: Status
—
Verfahrensart
Verfahrensantrag
Kategorie
Rücknahmeanträge
Parteien: Kläger
DexCom, Inc.
Vertreter: Markus Grosch (Quinn Emanuel Urquhart & Sullivan LLP); Johannes Bukow (Quinn Emanuel Urquhart & Sullivan LLP); Jan Axtmann (Quinn Emanuel Urquhart & Sullivan LLP); Paul Lehmann (Quinn Emanuel Urquhart & Sullivan LLP)
Beklagte
Abbott Laboratories
Abbott Diabetes Care Inc.
Abbott GmbH
Abbott Diagnostics GmbH
Abbott Laboratories GmbH
Abbott Logistics B.V.
Abbott France (S.A.S.)
Abbott s.r.l.
Abbott Gesellschaft m.b.H.
Abbott B.V.
Abbott (S.A./N.V.)
Abbott Scandinavia Aktiebolag
Abbott Oy
Division: Dusseldorf LD
Richter: Ronny Thomas · Presiding judge
Berenice Thom · Legally qualified judge
Petri Rinkinen · Legally qualified judge
Claus Elmeros · Technically qualified judge
Technology: Pharmaceutical & Medical
Sprache: —
Erste Entscheidung: 7. Jan. 2025

Entscheidungen

2025-01-07
ZurückgenommenApplication Rop 265
Düsseldorf Local Division decision allowing the withdrawal of DexCom's infringement action (including application to amend the patent) and Abbott's counterclaim for revocation by mutual consent (R. 265 RoP). Following an out-of-court settlement, DexCom agreed to withdraw the infringement action and Abbott agreed to withdraw the revocation counterclaim. Neither party requested a costs decision. The oral hearing scheduled for 8 May 2025 was cancelled. Court fees reimbursed: DexCom receives 60% of infringement action fees (EUR 22,200), Abbott receives 60% of revocation counterclaim fees (EUR 12,000).
Rechtsfragen:Withdrawal of action by mutual consent (R. 265 RoP)SettlementCourt fee reimbursement (R. 370.11, R. 370.9(b)(i) RoP)

Dokumente